Nivolumab Combined With Daratumumab With or Without Low-dose Cyclophosphamide
Status:
Active, not recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
Evaluation of the effect of nivolumab and daratumumab with or without low-dose
cyclophosphamide in patients with relapsed/refractory multiple myeloma.
Phase:
Phase 2
Details
Lead Sponsor:
VU University Medical Center
Collaborators:
Albert Schweitzer Hospital Erasmus Medical Center Isala Maastricht University Medical Center Meander Medical Center Radboud University Rijnstate Hospital St. Antonius Hospital UMC Utrecht University Medical Center Groningen